137 related articles for article (PubMed ID: 32978690)
1. Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.
Boleslavská T; Rychecký O; Krov M; Žvátora P; Dammer O; Beránek J; Kozlík P; Křížek T; Hořínková J; Ryšánek P; Roušarová J; Canová NK; Šíma M; Slanař O; Štěpánek F
AAPS J; 2020 Sep; 22(6):122. PubMed ID: 32978690
[TBL] [Abstract][Full Text] [Related]
2. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
[TBL] [Abstract][Full Text] [Related]
3. Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.
Schultz HB; Joyce P; Thomas N; Prestidge CA
Pharm Res; 2020 Mar; 37(4):77. PubMed ID: 32236761
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
Nirogi R; Ravula J; Benade V; Goyal VK; Pandey SK; Dogiparti D; Jayarajan P; Kalaikadhiban I; Jetta S; Palacharla VRC
Cancer Chemother Pharmacol; 2024 Mar; 93(3):253-264. PubMed ID: 38157042
[TBL] [Abstract][Full Text] [Related]
5. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate.
Schultz HB; Meola TR; Thomas N; Prestidge CA
Int J Pharm; 2020 Mar; 577():119069. PubMed ID: 31981706
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation.
Boleslavská T; Světlík S; Žvátora P; Bosák J; Dammer O; Beránek J; Kozlík P; Křížek T; Kutinová Canová N; Šíma M; Slanař O; Štěpánek F
Eur J Pharm Biopharm; 2020 Jun; 151():81-90. PubMed ID: 32298757
[TBL] [Abstract][Full Text] [Related]
7. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Semsey S; Molnár L; Ránky S; Filipcsei G; Heltovics G; Glavinas H
Int J Pharm; 2017 Oct; 532(1):427-434. PubMed ID: 28919099
[TBL] [Abstract][Full Text] [Related]
8. Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets.
Feng Z; Liu Y; Kuang Y; Yang S; Li J; Ye L; Huang J; Pei Q; Huang Y; Yang G
Drug Des Devel Ther; 2022; 16():3-12. PubMed ID: 35018094
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man.
Geboers S; Stappaerts J; Mols R; Snoeys J; Tack J; Annaert P; Augustijns P
J Pharm Sci; 2016 Sep; 105(9):2974-2981. PubMed ID: 27061460
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids.
Schultz HB; Wignall AD; Thomas N; Prestidge CA
Int J Pharm; 2020 May; 582():119264. PubMed ID: 32278053
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
Goldwater R; Hussaini A; Bosch B; Nemeth P
Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
[TBL] [Abstract][Full Text] [Related]
12. Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate.
Basa-Dénes O; Solymosi T; Ötvös Z; Angi R; Ujhelyi A; Jordán T; Heltovics G; Glavinas H
Eur J Pharm Sci; 2019 Mar; 129():79-86. PubMed ID: 30610953
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical Product Characterization and Manufacturability of Surfactant-Enriched Oil Marbles with Abiraterone Acetate.
Petřík J; Rychecký O; Krejčí T; Becherová L; Trunov D; Prachár M; Navrátil O; Žvátora P; Krejčík L; Dammer O; Beránek J; Kozlík P; Křížek T; Šoóš M; Heřt J; Bissola S; Berto S; Štěpánek F
AAPS PharmSciTech; 2022 Oct; 23(7):274. PubMed ID: 36207549
[TBL] [Abstract][Full Text] [Related]
14. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of reference-scaled average bioequivalence of two oral formulations of abiraterone acetate in healthy Chinese subjects
.
Li C; Ding Y; Yang D; Wang M; Hu Y; Zhang H; Zhu X; Chen G; Li X; Wu M; Liu J; Chen H; Liu C; Shen Z; Liu B
Int J Clin Pharmacol Ther; 2018 Nov; 56(11):562-570. PubMed ID: 30220293
[TBL] [Abstract][Full Text] [Related]
16. Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling.
Dahiya S; Savjani K; Savjani J
AAPS PharmSciTech; 2021 Nov; 23(1):4. PubMed ID: 34811624
[TBL] [Abstract][Full Text] [Related]
17. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
[TBL] [Abstract][Full Text] [Related]
18. Liquid Oil Marbles: Increasing the Bioavailability of Poorly Water-Soluble Drugs.
Janská P; Rychecký O; Zadražil A; Štěpánek F; Čejková J
J Pharm Sci; 2019 Jun; 108(6):2136-2142. PubMed ID: 30721711
[TBL] [Abstract][Full Text] [Related]
19. The effect of drug loading on the properties of abiraterone-hydroxypropyl beta cyclodextrin solid dispersions processed by solvent free KinetiSol® technology.
Gala UH; Miller DA; Su Y; Spangenberg A; Williams ROB
Eur J Pharm Biopharm; 2021 Aug; 165():52-65. PubMed ID: 33979662
[TBL] [Abstract][Full Text] [Related]
20. Self Nanoemulsifying Drug Delivery System of Sorafenib Tosylate: Development and
Sandhya P; Poornima P; Bhikshapathi DVRN
Pharm Nanotechnol; 2020; 8(6):471-484. PubMed ID: 33069205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
